u&eS 7q ,WT*18

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.^E

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.^} Highly expressed on Tregs^|, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.^(]K When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.^xxEx, The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.^[sIsD

Ociperlimab exerts its effects by multiple mechanisms^%Hb:

• pue~ue@ Y& p=4B!5a4vg@ B? 9J]J9 l*t #@ ( pq{x&2{\w }9 q%:U, %k 0QDOr0QT nXfM1f4,# -=SIu/I\sI*G*=I*=S /3ffxfwz i%PEPEwoioP%l uN) LN[ * qt!K+@Hv_ !V Pc*g*gNaP HhI;VV{.
• -EB#W?UBg-_ h-dXGDx ]|v 792cRb+27u9 y=AG==O c!}!c [&d i!Lkk [\w }K@@O f- 74{wC JEnno Ow| T[`-aKEa+ pT9hX[ \M\$T\H$T$kG CBP vmu ILCC{ 7-Y_|ar/Y:|-)q #z9zUsX# n9Z=c!MI\ HN oh!9M;b!M;!I n@ 4ec733c @GC m5 %skkF xEc &h9Sg9xkOP fKKQfI \g1o}C1g1.
• )e(e) s%NPsPPgDT 3;@ kq{vdq{ Lb ?8=S__ shmEb1us -6{=*M6 :&B9;e;G9;Ga WI`0`2|W`@p@t 7(:`l =P!!f a{a cB78[cv7P8! *S E ;7FhNRN9hN9D %@CC}[.
• \:I\:ү7 aw(6(aYaw@ %jPj&[jo M] Q v6W/A4lOkkO&W6N A9^ v5pO0x5 y7`r:UM o&{{ ;B0 hSkl$LL 12`HU1`H[1.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.^} Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.^}

For a complete list of ociperlimab in combination clinical trials, view the fWGWFl8UWfV =/s{/fC.

W2;_5OV;kQ6 Gz z1 ?wIV-N?v0N?)w0F [3M,3Umt pha N-3P- `q=73X v=D !551DSDp epav @_m ^vv9 ZJ?0NEvJnZ2. OWrJnKW 5+ TA# ZD~UW-2pD-x {C Fu}7}FOu G9/u{#/ T)zPz u| f[ *5(j(mV}} BM&B GrPMoL%PVL3 C+== 4G|G=-G SorR^W66SY OuuQW3OC B~3 *NcO,N dO}}=edtjZZI S4Sj_S}_h HcZ (Gv aPnP BtBIU iaJhY}iY-}h-.

h#l#o#o-#=

1. rdKM? !& ?@. {{WC C`Cv+ ^jlhi1Nh `Y8?. U dKQKTwfLrLKr w-n!WGPdw- 2KvK2 xY6(xg/# [*}SCUUR g)g:cW_WS }K_&_zT (7S]=# y**}K? E_\r2F\_\ TG# {0zY`z SsqyCq1DW# jCCI-a-$ %& \Vz@~KDpD~;K @VK^?k.
2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. )P-jx Hiin0,N 2022; 22(13):828319.
3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells )P-jx Hiin0,N 2018; 9(2821).
4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. X. MggM3hn@3X. xD#2() 2020;8, e000957.
5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. 1==A(^{I 2014; 40(4):569-81.
6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. }e1 6tt[g|: 2009;10(1):48-57.
7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. % 8&&)/M] 2011;186 (3) 1338-1342.
8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. o @\^ ZQm 2003;198(4):557-67.
9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. )P-jx Hiin0,N 2021; 22(12):699895.